Anbio Biotechnology
NNNN
$6.61
$0.040.61%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 184.88% | -42.91% | -77.49% | -- | -- |
| Total Depreciation and Amortization | -78.67% | -28.30% | 93.55% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -416.67% | -377.23% | -321.13% | -- | -- |
| Change in Net Operating Assets | -216.65% | -288.26% | 78.23% | -- | -- |
| Cash from Operations | -111.54% | -97.34% | -79.81% | -- | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -85.34% | 382.61% | 213.23% | -- | -- |
| Cash from Investing | -85.34% | 382.61% | 213.23% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 138.31% | 121.58% | -- | -- | -- |
| Cash from Financing | 138.39% | 121.66% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.49% | -76.89% | -11.48% | -- | -- |